



ELEKTA INITIATES REPURCHASE OF OWN SHARES

PRESS RELEASE

Stockholm, June 21, 2006

Elekta has on June 21, 2006, repurchased 54.500 B shares at an average price of SEK 125.86. Elekta's current holding of own shares (treasury stock) amounts to 54.500 B shares. The total number of shares in Elekta as of June 20 is 94,345,904.

The repurchases currently being carried out are in line with the Board's decision on June 14, 2006, to mandate executive management to initiate on appropriate occasions the repurchase of shares amounting up to SEK 100 M.

For information regarding implementation of additional purchases within this mandate, Elekta offers reference continually to www.elekta.com – Investor Center or to www.stockholmsborsen.se.

Purchases will be made on the Stockholm Stock Exchange and at a price within the registered price interval at the time of each purchase. Purchases may be made during the period until the next Annual General Meeting. Elekta intends to suggest to the AGM that repurchased shares are cancelled.

For further information, please contact:

Peter Ejemyr
Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000
e-mail: peter.ejemyr@elekta.com

About Elekta

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife[®] for non-invasive treatment of brain disorders and Elekta Synergy[®] for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.

Elekta's systems and solutions are used at over 3,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approx. 1850 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTA. For more information about Elekta, please visit www.elekta.com.